Patents by Inventor Ziqing KONG

Ziqing KONG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240110929
    Abstract: The present invention provides a screening kit and a confirmed and typing diagnosis system for primary aldosteronism. A sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the six markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the six markers such as, aldosterone on the same platform. Therefore, the present invention is integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.
    Type: Application
    Filed: December 1, 2023
    Publication date: April 4, 2024
    Inventors: Pengyun LIU, Xiaofen YUAN, Jinfei MA, Ziqing KONG, Yikun LI, Weijia WU, Huafen LIU
  • Patent number: 11923082
    Abstract: The present invention relates to a system for predicting gestational diabetes mellitus (GDM) of pregnant individuals, wherein the system comprises an operation module, and the operation model comprises a support vector regression model, and the system is used to predict the plasma glucose levels at 1 hour and/or 2 hours of oral glucose tolerance test (OGTT) by using a support vector regression developed prediction model generated by substituting the concentration of the biomarkers in fasting blood samples of pregnant individuals. The present invention provides biomarkers and biomarker-based diagnostic models for differential diagnosis of gestational diabetes mellitus (GDM), which can be applied to diagnosis or prediction of GDM in early stage and are of great significance to the prevention or treatment of GDM.
    Type: Grant
    Filed: June 10, 2022
    Date of Patent: March 5, 2024
    Assignees: HANGZHOU CALIBRA DIAGNOSTICS CO., LTD., HANGZHOU DIAN MEDICAL INSPECTION CENTER CO., LTD.
    Inventors: Huafen Liu, Ziqing Kong, Chao Zhang, Rongchang Chen, Yuning Zhu
  • Publication number: 20240019449
    Abstract: In a screening kit and a confirmed and typing diagnosis system for primary aldosteronism, a sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the five markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the five markers such as, aldosterone on the same platform. Therefore, the screening kit and confirmed and typing diagnosis system for primary aldosteronism are integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.
    Type: Application
    Filed: April 21, 2023
    Publication date: January 18, 2024
    Inventors: Pengyun LIU, Xiaofen YUAN, Jinfei MA, Ziqing KONG, Yikun LI, Weijia WU, Huafen LIU
  • Patent number: 11860171
    Abstract: In a screening kit and a confirmed and typing diagnosis system for primary aldosteronism, a sample is pretreated by a magnetic bead bonded with a balanced hydrophilic-lipophilic polymer on the surface thereof, and process conditions are optimized and the content of each the five markers such as, aldosterone in the sample is accurately detected by liquid chromatography-tandem mass spectrometry for one time, thus finding the optimal screening cut-off value of 20.4; when a positive result is judged, PA is confirmed and subjected to typing diagnosis according to the test values of the markers, thereby achieving the simultaneous detection of the content of each the five markers such as, aldosterone on the same platform. Therefore, the screening kit and confirmed and typing diagnosis system for primary aldosteronism are integrated with screening, confirmed and typing diagnosis functions, thus providing a reliable laboratory examination basis for clinicians to formulate an effective therapeutic regimen.
    Type: Grant
    Filed: April 21, 2023
    Date of Patent: January 2, 2024
    Assignee: HANGZHOU CALIBRA DIAGNOSTICS CO., LTD.
    Inventors: Pengyun Liu, Xiaofen Yuan, Jinfei Ma, Ziqing Kong, Yikun Li, Weijia Wu, Huafen Liu
  • Publication number: 20230402131
    Abstract: The present disclosure provides a biomarker for detecting colorectal cancer and a use thereof. A metabolomics method is used to analyze metabolites with significant differences in urine of patients with colorectal cancer and normal people, such that a series of biomarkers capable of early predicting an occurrence risk of colorectal cancer are screened out, a group of biomarkers are further screened to construct a diagnostic model for colorectal cancer, and the model can be used for conveniently, non-invasively and effectively predicting whether an individual suffers from colorectal cancer, and meets clinical needs.
    Type: Application
    Filed: December 2, 2022
    Publication date: December 14, 2023
    Inventors: Rongchang CHEN, Sheng QUAN, Chao ZHANG, Ziqing KONG, Pengyun LIU, Huafen LIU
  • Publication number: 20230307120
    Abstract: The present invention relates to a system for predicting gestational diabetes mellitus (GDM) of pregnant individuals, wherein the system comprises an operation module, and the operation model comprises a support vector regression model, and the system is used to predict theplasma glucose levels at 1 hour and/or 2 hours of oral glucose tolerance test (OGTT) by using a support vector regression developed prediction model generated bysubstituting the concentration of the biomarkers in fasting blood samples of pregnant individuals. The present invention provides biomarkers and biomarker-based diagnostic models for differential diagnosis of gestational diabetes mellitus (GDM), which can be applied to diagnosis or prediction of GDM in early stage and are of great significance to the prevention or treatment of GDM.
    Type: Application
    Filed: June 10, 2022
    Publication date: September 28, 2023
    Inventors: Huafen LIU, Ziqing KONG, Chao ZHANG, Rongchang CHEN, Yuning ZHU
  • Publication number: 20220390472
    Abstract: The present invention provides a synchronous detection method of medicaments influencing ARR in the detecting process of renin activity by liquid chromatography-tandem mass spectrometry. The method achieves the qualitative screening of medicaments influencing ARR values while detecting plasma renin activity by liquid chromatography-tandem mass spectrometry; moreover, the method can be used to assist to analyze and judge ARR as negative, positive, false negative or false positive. The detecting method achieves effective extraction of angiotensin I and 43 hypertension therapeutics synchronously through protein precipitation to samples, and enables to perform synchronous detection of a plurality of indices including angiotensin I and 43 hypertension therapeutics on the extracted sample by liquid chromatography-tandem mass spectrometry technology of high throughput, high specificity and high sensitivity.
    Type: Application
    Filed: October 5, 2021
    Publication date: December 8, 2022
    Inventors: Pengyun LIU, Ziqing KONG, Jinfei MA, Xiaofen YUAN, Huafen LIU